XPO1 and Miyoshi myopathy: Thus, XPO1 inhibition can overcome PI resistance in MM cells in cell lines as well as in patient-derived MM cells ex vivo [8, 14, 17], and selinexor was shown to sensitise PI-refractory MM cells to bortezomib and carfilzomib [16].